🎯 Anti-NGF Therapy Osteoarthritis Pain Trial Simulator

Trial Enrollment — Finding the Right OA Patients

Screening identifies moderate-to-severe OA patients failing standard pain therapy.

• 2,400: Patients screened (across trial sites)
• 696: Patients enrolled (met strict criteria)
• 100%: Prior therapy failure (inadequate pain relief)
• 2–4: Kellgren-Lawrence grade (radiographic OA severity)

Eligibility criteria

Adults with chronic knee or hip OA pain qualify. Radiographs must confirm moderate-to-severe joint damage. Prior NSAID or opioid therapy must have failed.

Baseline pain burden

Baseline WOMAC pain scores average sixty-five of one hundred. Daily pain limits walking, stairs, and standing. Patients report OA pain as their top burden.

Consent and safety screening

Informed consent covers joint safety monitoring requirements. Joint imaging rules out rapidly progressive OA risk. Cardiovascular and neurologic history are also reviewed.

Randomization — Splitting Patients into Trial Arms

Enrolled patients are randomly assigned to anti-NGF or placebo.

• 1:1: Randomization ratio (anti-NGF to placebo)
• 348: Anti-NGF arm (patients assigned)
• 348: Placebo arm (patients assigned)
• Double: Blinding (patient and assessor)

Randomization method

A computer-generated sequence assigns each patient an arm. Stratification balances baseline pain severity across both arms. Site staff cannot predict the next assignment.

Double-blind design

Neither patients nor assessors know arm assignment. Identical-looking injections prevent expectation bias in reporting. Unblinding only occurs for safety emergencies.

Why placebo control matters

OA pain fluctuates and responds strongly to placebo. A control arm isolates the true drug effect. Without it, natural improvement could be misread as efficacy.

Treatment Period — Dosing Across Sixteen to Twenty-Four Weeks

Patients receive scheduled doses and follow-up visits over months.

• 8 wks: Dosing interval (subcutaneous injection)
• 16–24 wk: Treatment duration (trial follow-up window)
• 6: Follow-up visits (per patient scheduled)
• <8%: Discontinuation rate (across both arms)

Dosing regimen

Anti-NGF antibody is injected subcutaneously every eight weeks. Placebo patients receive an identical-appearing injection schedule. Doses are weight-based and pharmacist-prepared.

Safety monitoring

Joint exams screen for rapidly progressive OA changes. Patients report numbness, tingling, or new joint symptoms. Sympathetic nervous system side effects are tracked closely.

Adherence and retention

Diaries capture daily pain and rescue medication use. Missed visits are minimized through patient reminder calls. High retention preserves statistical power at endpoint.

Primary Endpoint Assessment — Scoring Pain and Function

Pain and physical function are measured at the endpoint visit.

• Wk 16: Primary endpoint (WOMAC pain change)
• Function: Co-primary measure (WOMAC subscale)
• PGA-OA: Patient global rating (secondary measure)
• ≥50%: Responder threshold (pain reduction)

WOMAC pain subscale

Five questions score pain during walking, stairs, and rest. Scores range zero to one hundred, lower is better. Change from baseline is the primary endpoint.

WOMAC function subscale

Seventeen items assess daily activities like rising and bathing. Function score change is the key co-primary endpoint. Both scales are patient-reported and validated.

Statistical analysis plan

A mixed model compares arms while accounting for dropouts. Significance is set at a two-sided p<0.05. Effect size is also reported for clinical relevance.

Trial Outcome — Anti-NGF Outperforms Placebo

The anti-NGF arm shows significantly greater pain and function gains.

• −65%: Pain reduction, anti-NGF (from baseline)
• −29%: Pain reduction, placebo (from baseline)
• +2×: Function improvement (vs placebo arm)
• Monitored: Joint safety signal (rapid OA progression)

Efficacy result

Anti-NGF patients report much larger pain score drops. Function gains are roughly double the placebo arm. Differences reach statistical and clinical significance.

Safety trade-offs

A small subset shows rapidly progressive joint damage. Regulators require joint imaging monitoring after approval. Dose and duration limits reduce this risk.

What comes next

Positive results support regulatory submission for approval. Long-term extension studies track durability and safety. Real-world registries will monitor joint outcomes further.